Drugs for AIDS/HIV: assessing the evidence.
This article highlights factors that may cause bias in individual controlled trials or meta-analysis of zidovudine (AZT) in HIV disease. The overall benefit of AZT and antiretroviral drug combinations in the progression of HIV disease is probably greater than has been or can ever be shown in an ethical controlled trial.
J L
JL
Jones
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D015982:Bias; D002985:Clinical Protocols; D004359:Drug Therapy, Combination; D015497:HIV-1; D006801:Humans; D015201:Meta-Analysis as Topic; D010352:Patient Dropouts; D010419:Pentamidine / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000706:statistics & numerical data; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D000935:Antifungal Agents; D015215:Zidovudine; D010419:Pentamidine